| Name | Title | Contact Details |
|---|
Handbooks in Health Care Company is a Newtown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
INTEGRIS Health is Oklahoma`s largest health system with hospitals, rehabilitation centers, physician clinics, mental health facilities, independent living centers and home health agencies located throughout the state. INTEGRIS Health is a not-for-profit corporation. It was organized under the laws of the state of Oklahoma for charitable, scientific and educational purposes and specifically to engage in the delivery of health-care services and related activities. INTEGRIS Health is governed by an 11 to 15-member board of directors made up of business and community leaders from across the state. It`s managed by President and Chief Executive Officer Bruce Lawrence, with the assistance of senior staff in the areas of physician services, facility operations, strategic services and finance. INTEGRIS Health is a not-for-profit corporation formed in 1983 to serve as the parent corporation for, and to provide management and administrative support to, INTEGRIS Baptist Medical Center Inc., another Oklahoma not-for-profit corporation that operates a tertiary care hospital in northwest Oklahoma City. In 1994, INTEGRIS Health merged with Baptist Healthcare of Oklahoma, an event that brought to the organization a network of outstanding rural hospitals across the state. In 1995, INTEGRIS Health merged with Southwest Medical Center, an acute-care hospital in southwest Oklahoma City. Each of these organizations brings a rich history of serving Oklahomans. INTEGRIS Health, along with these and a number of other affiliated entities, form the INTEGRIS Health system.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
Imedex is a Alpharetta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OHCOW is a Windsor, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.